Candesartan-based regimens produced no significant difference in cardiovascular morbidity or mortality compared to amlodipine-based regimens (HR 1.01; 95% CI 0.79-1.28; P=0.969).
RCT (n=4,728)
Open-label, blinded endpoint assessment
randomized
Does a candesartan-based regimen reduce cardiovascular events compared to an amlodipine-based regimen in high-risk hypertensive patients?
Candesartan and amlodipine provide comparable protection against cardiovascular events in high-risk hypertensive patients, though candesartan is associated with a lower incidence of new-onset diabetes.
Effect estimate: HR 1.01 (95% CI 0.79-1.28)
Absolute Event Rate: 5.67% vs 5.67%
p-value: p=0.969
The Candesartan Antihypertensive Survival Evaluation in Japan Trial was designed to compare the long-term effects of the angiotensin II receptor blocker candesartan and the calcium channel blocker amlodipine on the incidence of cardiovascular events, represented as a composite of sudden death and cerebrovascular, cardiac, renal, and vascular events in high-risk Japanese hypertensive patients. We conducted a prospective, randomized, open-label study with blinded assessment of the end point in 4728 Japanese hypertensive patients (mean age: 63.8 years; mean body mass index: 24.6 kg/m(2)). Patients were followed for an average of 3.2 years. Blood pressure was well controlled with both treatment-based regimens (systolic blood pressure/diastolic blood pressure: 136.1/77.3 mm Hg for candesartan-based regimens and 134.4/76.7 mm Hg for amlodipine-based regimens after 3 years). Primary cardiovascular events occurred in 134 patients with both the candesartan- and amlodipine-based regimens. The 2 treatment-based regimens produced no significant differences in cardiovascular morbidity or mortality in the high-risk Japanese hypertensive patients (hazard ratio: 1.01; 95% CI: 0.79 to 1.28; P=0.969). In each primary end point category, there was no significant difference between the 2 treatment-based regimens. New-onset diabetes occurred in fewer patients taking candesartan (8.7/1000 person-years) than in those taking amlodipine (13.6/1000 person-years), which resulted in a 36% relative risk reduction (hazard ratio: 0.64; 95% CI: 0.43 to 0.97; P=0.033). We disclosed that candesartan-based and amlodipine-based regimens produced no statistical differences in terms of the primary cardiovascular end point, whereas candesartan prevented new-onset diabetes more effectively than amlodipine.
Ogihara et al. (Thu,) conducted a rct in Hypertension with high cardiovascular risks (n=4,728). Candesartan vs. Amlodipine was evaluated on Composite of sudden death and cerebrovascular, cardiac, renal, and vascular events (HR 1.01, 95% CI 0.79-1.28, p=0.969). Candesartan-based regimens produced no significant difference in cardiovascular morbidity or mortality compared to amlodipine-based regimens (HR 1.01; 95% CI 0.79-1.28; P=0.969).